Eupraxia Pharmaceuticals (EPRX) Common Equity (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Common Equity of $136.2 million for Q1 2026, up 403.78% year-over-year from $27.0 million in Q1 2025, and up 69.29% quarter-over-quarter from $80.4 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Common Equity (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Common Equity for 5 consecutive years, with $136.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 403.78% year-over-year to $136.2 million; the TTM figure through Mar 2026 stood at $136.2 million (up 403.78% YoY), while the FY2025 annual figure was $80.4 million, up 140.82% from the prior year.
- Common Equity advanced to $136.2 million in Q1 2026 per EPRX's latest filing, from $80.4 million in the prior quarter.
- Across five years, Common Equity topped out at $136.2 million in Q1 2026 and bottomed at $892326.0 in Q4 2023.
- Historically, Common Equity has averaged $39.5 million across 5 years, with a median of $21.0 million in 2025.
- Annual changes were most pronounced in 2023 — Common Equity plunged 87.62% — and 2024, when it jumped 3643.56%.
- Eupraxia Pharmaceuticals' Common Equity stood at $7.2 million in 2022, then slumped by 87.62% to $892326.0 in 2023, then surged by 3643.56% to $33.4 million in 2024, then soared by 140.82% to $80.4 million in 2025, then jumped by 69.29% to $136.2 million in 2026.
- Business Quant data shows EPRX's Common Equity at $136.2 million in Q1 2026, $80.4 million in Q4 2025, and $88.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 136.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136.19 Mn |
| Dec 31, 2025 | 80.45 Mn |
| Sep 30, 2025 | 88.44 Mn |
| Jun 30, 2025 | 20.98 Mn |
| Mar 31, 2025 | 27.03 Mn |
| Dec 31, 2024 | 33.40 Mn |
| Sep 30, 2024 | 7.98 Mn |
| Jun 30, 2024 | 13.34 Mn |
| Mar 31, 2024 | 18.11 Mn |
| Dec 31, 2023 | 892,326.00 |
| Dec 31, 2022 | 7.21 Mn |